Back
Science

Study Reports Combined Therapy for Obesity Enhances Fat Loss While Preserving Lean Mass

Generated on: Last updated: 2 sources
View source

Breakthrough Combination Therapy Achieves Significant Fat Loss While Preserving Muscle Mass

A recent study published in Nature Medicine reveals a promising new approach to weight management, combining semaglutide with bimagrumab. The BELIEVE study, funded by Eli Lilly and Company, found that this dual therapy led to greater weight loss while largely preserving lean body mass, addressing a key challenge in obesity treatment. The 72-week, double-blind, placebo-controlled investigation also reported improvements in inflammatory markers and insulin sensitivity.

"Combining semaglutide, a GLP-1 receptor agonist, with bimagrumab, an antibody that blocks activin signaling pathways, resulted in greater weight loss while largely preserving lean body mass."

Addressing Lean Mass Loss in Obesity Treatment

Current GLP-1-based therapies, while effective for weight loss, often lead to a significant reduction in lean body mass, sometimes accounting for up to 40% of the total weight lost. This challenge was a primary focus of the BELIEVE study.

Dr. Steven Heymsfield, associated with both LSU and Pennington Biomedical Research Center, emphasized that "patients with obesity who are at risk for low muscle mass could benefit from treatments designed to maximize fat reduction while preserving skeletal muscle."

Researchers hypothesized that combining semaglutide and bimagrumab, which operate through distinct biological pathways, could offer an additive effect, leading to greater fat reduction and better preservation of lean mass.

Study Design

The BELIEVE study involved participants assigned to nine randomized groups. These groups received either bimagrumab only (administered every 12 weeks), semaglutide only (administered weekly), or various combinations of both drugs.

Remarkable Weight Loss with Preserved Lean Mass

The study's key findings highlight significant differences in weight loss and body composition across the treatment groups:

  • Bimagrumab Only: Participants experienced an average 10.8% weight loss. Notably, this loss was entirely attributed to fat mass, accompanied by a 2.5% increase in lean mass.
  • Semaglutide Only: This group achieved an average 15.7% body weight loss, with 71.8% of this reduction consisting of fat mass.
  • Combination Therapy (Semaglutide + Bimagrumab): The most striking results were observed here, with participants achieving an average 22.1% weight loss. Crucially, an impressive 92.8% of this loss was composed of fat mass, with lean mass largely preserved.

The combination therapy delivered nearly double the fat mass reduction compared to semaglutide alone, while effectively safeguarding muscle mass.

Broader Health Improvements Uncovered

Beyond the notable changes in weight and body composition, the BELIEVE study also documented several other significant health benefits:

  • Reduced Inflammation: Participants saw a substantial decrease of up to 83% in high-sensitivity C-reactive protein (hsCRP), a key marker for inflammation and cardiovascular risk.
  • Enhanced Metabolic Health: There was a substantial increase in adiponectin, a crucial hormone known for its links to improved insulin sensitivity, optimized fat metabolism, and anti-inflammatory effects.
  • Prediabetes Reversion: In a specific subgroup identified with prediabetes, some combination therapy groups achieved a remarkable 100% reversion to normoglycemia, indicating a complete return to normal blood sugar levels.

Tolerability and A Glimpse into the Future

The combination therapy was generally well tolerated, with adverse events aligning with the known safety profiles of the individual drugs. Common side effects reported in groups receiving bimagrumab included mild-to-moderate acne and muscle spasms.

Researchers advocate for continued clinical development of this promising drug combination. The study also puts forth a significant recommendation for the future of obesity management:

"A shift in the focus of obesity management from traditional metrics like weight and body mass index (BMI) to a more detailed understanding of body composition."

This research was funded by Eli Lilly and Company and designed by Versanis Bio, a wholly owned subsidiary of Eli Lilly and Company.